Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

Marden, Emily; Ntai, Ioanna; Bass, Scott; Flühmann, Beat

Marden, Emily; Ntai, Ioanna; Bass, Scott; Flühmann, Beat.

Afiliação

Marden E; Food, Drug and Medical Device Regulatory Law, Sidley Austin LLP, Palo Alto, California, USA.
Ntai I; Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland.
Bass S; Global Life Sciences, Sidley Austin LLP, Washington, D.C., USA.
Flühmann B; Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland. beat.fluehmann@viforpharma.com.

AAPS J ; 20(6): 104, 2018 09 25.

Article em En | MEDLINE | ID: mdl-30255312

ABSTRACT

ABSTRACT

In the published article the given name and the family name for each author is listed in the incorrect order and therefore cited incorrectly. The correct order (given name followed by family name) of names is listed above.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google